Group 1 - The core product developed by the company, a combination of Ploglitazone, Dapagliflozin, and Metformin, has been approved for clinical trials in China by the National Medical Products Administration [1] - This product is the world's first clinically approved three-drug combination formulation for diabetes management [1] - The mechanism of action of the components is complementary, addressing multiple pathophysiological mechanisms of diabetes, which can effectively control blood sugar levels [2] Group 2 - The approved clinical indication is for adult patients with type 2 diabetes who have inadequate blood sugar control with Metformin alone, in conjunction with diet and exercise [2] - The combination therapy aims to reduce the number of medications needed, simplify the treatment regimen, and improve patient adherence to therapy [2] - This product will provide a new treatment option for type 2 diabetes patients and further enrich the company's product line in the metabolic disease sector [2]
石药集团：普卢格列汀达格列净二甲双胍缓释片在中国获临床试验批准